Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II) (ORBIT-AF II)
|ClinicalTrials.gov Identifier: NCT01701817|
Recruitment Status : Completed
First Posted : October 5, 2012
Last Update Posted : December 15, 2017
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation||Other: Patients with Atrial Fibrillation|
|Study Type :||Observational|
|Actual Enrollment :||13785 participants|
|Official Title:||Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II)|
|Actual Study Start Date :||February 20, 2013|
|Actual Primary Completion Date :||July 12, 2017|
|Actual Study Completion Date :||July 12, 2017|
Patients with Atrial Fibrillation (AF)
(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
Other: Patients with Atrial Fibrillation
Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
- Number of major bleeding events [ Time Frame: 2 years ]Major bleeding will be defined according to International Society of Thrombosis and Hemostasis (ISTH) criteria.
- Number of major adverse cardiac events [ Time Frame: 2 years ]Major cardiac events are defined as stroke or non-central nervous system (non-CNS) systemic embolism, myocardial infarction, and cardiovascular death.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01701817
Show 220 Study Locations
|Study Director:||Janssen Scientific Affairs, LLC Clinical Trial||Janssen Scientific Affairs, LLC|